BioNTech SE (BioNTech SE) Change In Payables And Accrued Expense : $143 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Change In Payables And Accrued Expense?

BioNTech SE's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $450 Mil. It means BioNTech SE's Accounts Payable & Accrued Expense increased by $450 Mil from Sep. 2023 to Dec. 2023 .

BioNTech SE's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $130 Mil. It means BioNTech SE's Accounts Payable & Accrued Expense increased by $130 Mil from Dec. 2022 to Dec. 2023 .

BioNTech SE Change In Payables And Accrued Expense Historical Data

The historical data trend for BioNTech SE's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Change In Payables And Accrued Expense Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-89.56

248.91

1,713.11

90.78

129.66

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-714.62	-922.48	642.15	-26.68	450.16

BioNTech SE Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $143 Mil.

BioNTech SE Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.